ArticleInvestigative ophthalmology & visual science2026
Clinical Surrogate Endpoints in Malattia Leventinese/Doyne Honeycomb Retinal Dystrophy: Findings From a Two-Year Natural History Study.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Malattia Leventinese/Doyne Honeycomb Retinal Dystrophy is a rare, inherited retinal dystrophy characterized by drusen formation and early vision loss. Its phenotypical similarities with dry age-related macular degeneration (AMD) make Malattia Leventinese a valuable monogenetic disease model for AMD. Identifying sensitive outcome measures is crucial for clinical trials. This study quantifies retinal pigment epithelium and drusen complex (RPEDC) increase and retinal layer degeneration using fully automated segmentation for multimodal imaging analysis, and investigates structural thresholds associated with functional decline through pointwise correlation. Methods: This multicenter cohort study included 25 patients (15 women and 10 men; median age = 60 years, interquartile range [IQR] = 51-73 years) with genetically confirmed Malattia Leventinese. Participants underwent multimodal imaging, including spectral-domain optical coherence tomography (SD-OCT), ultrawide fundus retinography and fundus autofluorescence (FAF), and mesopic and two-color scotopic microperimetry. Changes in retinal layer thicknesses and retinal sensitivity were assessed over 2 years using linear mixed-effects models, and structure-function breakpoints were estimated with piecewise models. Results: RPEDC thickness increased (+2.24 µm/y), whereas photoreceptor inner segments (-0.70 µm/y) and outer nuclear layer (-1.95 µm/y) thicknesses, in addition to choroidal thickness (-10.83 µm/y), decreased with disease progression. Total retinal thickness remained stable. Scotopic sensitivity declined over time, with -0.40 decibel (dB)/year at 505 nm and -0.37 dB/year at 627 nm, whereas mesopic sensitivity remained stable. Function decreased most in early disease stages, with the onset of drusen accumulation. Conclusions: In Malattia Leventinese, the total retinal thickness remains unchanged because the RPEDC increase offsets the thinning of outer retinal layers. Only scotopic function decreases significantly with progression and before the age of 55 years. Mesopic function may serve to track later stages. These findings support the outer nuclear layer and photoreceptor inner segment thicknesses as key structural endpoints and scotopic sensitivity as an early functional outcome measure for monitoring disease progression in ongoing and future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.